Log In
BCIQ
Print this Print this
 

oliceridine (TRV130)

  Manage Alerts
Collapse Summary General Information
Company Trevena Inc.
DescriptionG protein-biased mu opioid receptor (MOR; OPRM1) ligand
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain; Treat moderate to severe acute postoperative pain
Regulatory Designation U.S. - Breakthrough Therapy (Treat moderate to severe acute pain);
U.S. - Fast Track (Treat moderate to severe acute pain)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today